MedPath

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

Not Applicable
Recruiting
Conditions
Cardiomyopathy
Interventions
Diagnostic Test: KardiaRx ECG Screening
Registration Number
NCT06609174
Lead Sponsor
Mayo Clinic
Brief Summary

The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
First Degree RelativeKardiaRx ECG ScreeningSubjects who are first-degree relatives of patients with DCM
Primary Outcome Measures
NameTimeMethod
Number of First-Degree Relatives to complete the AI-ECGBaseline

Measured by the number of complete transmissions from the Kardia 6-lead device to the AI-ECG algorithm.

Number of First-Degree relatives to complete cardiac screeningBaseline

The following screening procedures will be considered a valid cardiac screening attempt:

* Scheduled or Completed TTE

* Scheduled or completed clinician visit for the purposes of generating a cardiac evaluation

Secondary Outcome Measures
NameTimeMethod
Number of subjects with an Left Ventricular Ejection Fraction ≤ 45%Baseline

Left Ventricular Ejection Fraction will be determined by AI-ECG

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath